A New iNKT-Cell Agonist-Adjuvanted SARS-CoV-2 Subunit Vaccine Elicits Robust Neutralizing Antibody Responses

By
Danielle Corrigan
-
0
77
Researchers found that a new invariant natural killer T (iNKT)-cell agonist αGC-CPOEt elicited a strong cytokine response with increased IL-4 production.
[ACS Infectious Diseases]
AbstractPress ReleaseGraphical Abstract